Table 4 Prevalence of TP53 germline variants in HBOC patients in Brazil.

From: Detection of germline variants in Brazilian breast cancer patients using multigene panel testing

Reference

n

Inclusion criteria

TP53 covered region

TP53 R337H, n (%)

TP53 mutations, n (%)

Region of Brazil

Palmero et al.9

750

Population screening

R337H

2 (0.3)

2 (0.3)

South

Assumpção et al.40

123

Unselected BC

Exon 10

3 (2.4)

3 (2.4)

Southeast

Gomes et al.41

390

Unselected BC

R337H

2 (0.5)

2 (0.5)

Southeast

Giacomazzi et al.45

815

Unselected BC

R337H

70 (8.6)

70 (8.6)

South/Southeast

Carraro et al.24

54

BC < 35 years

Complete gene with DS

0 (0.0)

1 (2)

Southeast

Giacomazzi et al.45

59

High-risk BC

R337H

2 (3.4)

2 (3.4)

South

Cury et al.44

28

High-risk BC

Complete gene with HRM

2 (7.1)

2 (7.1)

Southeast

Silva et al.27

120

High-risk BC

R337H

3 (2.5)

3 (2.5)

Southeast

Felix et al.30

106

High-risk BC

R337H

1 (0.9)

1 (0.9)

Northeast

da Costa E Silva Carvalho et al.39

94

High-risk BC

Complete gene with DS

5 (5.3)

6 (6.4)

Southeast

Bandeira et al.62

105

High-risk BC

Complete gene with DS

1 (0.9)

1 (0.9)

Southeast

Cipriano Jr et al.38

44

High-risk BC

R337H

1 (2.3)

1 (2.3)

Southeast

de Souza Timoteo et al.60

132

High risk BC

Complete gene with DS

0 (0.0)

0 (0.0)

Northeast

Gomes et al.48

126

High risk breast and ovarian cancer

Complete gene with DS

0 (0.0)

1 (0.8)

Southeast

Sandoval et al.46

224

High risk BC

Complete gene with DS

6 (2.7)

8 (3.6)

Central West

Guindalini et al. (current study)

1663

BC refered to GT

Complete gene with DS

26 (1.6)

37 (2.2)

All

  1. BC breast cancer, DS direct sequencing like Sanger or next generation sequencing (NGS), GT genetic testing, HRM high resolution melting.